Alice Bonneville-Levard

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Olivier Trédan, Qing Wang, Daniel Pissaloux et al. · Annals of Oncology · 2019 · 191 citations

Medicine, Molecular Medicine, Oncology +16

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)

Matthias Preusser, Antonio Silvani, Émilie Le Rhun et al. · Neuro-Oncology · 2021 · 78 citations · Full text

Medicine, Neurological Surgery, Oncology +11

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Loïc Lebellec, Bruno Chauffert, Jean‐Yves Blay et al. · European Journal of Cancer · 2017 · 56 citations

Medicine, Oncology, Surgery +13

MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation

Didier Frappaz, Marc Barritault, Laure Montané et al. · Neuro-Oncology · 2021 · 38 citations · Full text

Medicine, Oncology, Pharmacology +13

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Pierre-Étienne Heudel, Sylvie Chabaud, David Pérol et al. · ESMO Open · 2021 · 34 citations · Full text

Medicine, Immunology, Oncology +11